Interactions of a PPARGC1A variant and a PNPLA3 variant affect nonalcoholic steatohepatitis in severely obese taiwanese patients

Medicine (United States)

Volumn 95, Issue 12, 2016, Pages

  Tai, Chi Ming ^a,b   Huang, Chih Kun ^a   Tu, Hung Pin ^c,f   Hwang, Jau Chung ^d   Yeh, Ming Lun ^e   Huang, Chung Feng ^a,e   Huang, Jee Fu ^a,e   Dai, Chia Yen ^a,e   Chuang, Wan Long ^a,e   Yu, Ming Lung ^a,g,h  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d LIN SHIN HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f Faculty of Internal Medicine   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^h NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOKINASE REGULATORY PROTEIN; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING PROTEIN 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; UNCLASSIFIED DRUG; ADIPONUTRIN, HUMAN; GCKR PROTEIN, HUMAN; MEMBRANE PROTEIN; PPARGC1A PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY MASS; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; RISK FACTOR; TAIWANESE; ALLELE; BIOPSY; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; LIVER; MALE; MORBID OBESITY; PATHOLOGY; TAIWAN; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; ALLELES; BARIATRIC SURGERY; BIOPSY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; LIPASE; LIVER; MALE; MEMBRANE PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; POLYMORPHISM, GENETIC; TAIWAN; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84962189583     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003120     Document Type: Article

References (31)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
2. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011;26(Suppl 1):163-172.
3. Hsieh MH, Ho CK, Hou NJ, et al. Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C. Int J Obes (Lond). 2009;33:1309-1317.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346: 1221-1231.
5. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(Suppl 1):S5-10.
6. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519-1523.
7. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461-1465.
8. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148 M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883-1894.
9. Tai CM, Huang CK, Tu HP, et al. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease. Surg Obes Relat Dis. 2014;11:888-894.
10. Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7:e1001324.
11. Tan HL, Zain SM, Mohamed R, et al. Association of glucokinase regulatory gene polymorphisms with risk and severity of nonalcoholic fatty liver disease: an interaction study with adiponutrin gene. J Gastroenterol. 2014;49:1056-1064.
12. León-Mimila P, Vega-Badillo J, Gutiérrez-Vidal R, et al. A genetic risk score is associated with hepatic triglyceride content and nonalcoholic steatohepatitis in Mexicans with morbid obesity. Exp Mol Pathol. 2015;98:178-183.
13. Lin YC, Chang PF, Chang MH, et al. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr. 2014;99:869-874.
14. Hui Y, Yu-Yuan L, Yu-Qiang N, et al. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver Int. 2008;28:385-392.
15. Lin YC, Chang PF, Chang MH, et al. A common variant in the peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene is associated with nonalcoholic fatty liver disease in obese children. Am J Clin Nutr. 2013;97:326-331.
16. Lee WJ, Wang W. Bariatric surgery: Asia-Pacific perspective. Obes Surg. 2005;15:751-757.
17. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487-1495.
18. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-2474.
19. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32:3-13.
20. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
21. Estall JL, Kahn M, Cooper MP, et al. Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes. 2009;58:1499-1508.
22. Chen Y, Mu P, He S, et al. Gly482Ser mutation impairs the effects of peroxisome proliferator-activated receptor gamma coactivator-1alpha on decreasing fat deposition and stimulating phosphoenolpyr-uvate carboxykinase expression in hepatocytes. Nutr Res. 2013;33: 332-339.
23. Begriche K, Igoudjil A, Pessayre D, et al. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28.
24. Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:8713-8742.
25. He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285:6706-6715.
26. Li JZ, Huang Y, Karaman R, et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest. 2012;122:4130-4144.
27. Kumari M, Schoiswohl G, Chitraju C, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012;15:691-702.
28. Liang H, Xu J, Xu F, et al. The SRE motif in the human PNPLA3 promoter (-97 to-88bp) mediates transactivational effects of SREBP-1c. J Cell Physiol. 2015;230:2224-2232.
29. Sookoian S, Pirola CJ. PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma and nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18:6018-6026.
30. Zain SM, Mohamed Z, Mohamed R. A common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol. 2015;30: 21-27.
31. Gorden A, Yang R, Yerges-Armstrong LM, et al. Genetic variation at NCAN locus is associated with inflammation and fibrosis in nonalcoholic fatty liver disease in morbid obesity. Hum Hered. 2013;75: 34-43.